Non-invasive prenatal testing (NIPT) uses cell-free DNA (cfDNA) in mother’s blood to evaluate possible chromosomal conditions in a pregnancy and can be performed as early as 10 weeks of pregnancy using a single blood draw.
Roche offers the Harmony® prenatal test, with a focused and clinically-relevant menu that screens for trisomy 21, trisomy 18, and trisomy 13. Additional menu options include monosomy X, 22q11.2 microdeletion, other sex chromosome aneuploidies, and fetal sex.
The Harmony test has been used to screen over two million pregnancies1 and is trusted by patients, clinicians, and labs worldwide. Backed by the commitment and quality of Roche Diagnostics, the Harmony test is an opportunity to maximize your offering in the NIPT market.